This is a rare, severe genetic disorder that causes the body to store too much fat, especially cholesterol. It affects the liver, kidneys, and bones, leading to serious health problems. It's caused by a missing enzyme.
Every report comes from a Lived member, sent anonymously.
Have you had Stem Cell Transplant for Wolman Disease?
Wolman disease is the severe, infant-onset form of lysosomal acid lipase deficiency (LAL deficiency), a rare inherited condition in which the body cannot break down certain fats and cholesterol inside its cells. Those fats build up in the liver, spleen, intestines, adrenal glands and other organs, and the damage starts within the first weeks of life. Babies typically develop vomiting, diarrhea, fatty stools, a swollen belly from an enlarged liver and spleen, and poor weight gain because the gut cannot absorb nutrients properly. Jaundice (yellowing of the skin and eyes), anemia and liver scarring often follow. Without treatment, infants with this form usually do not survive their first year. Doctors now often call it infantile-onset or rapidly progressive LAL deficiency. A milder, later-onset form, once called cholesteryl ester storage disease, has the same genetic cause but some working enzyme remains; it usually appears in childhood or adulthood as an enlarged liver and high cholesterol, and follows a very different course.
Wolman disease is caused by changes in the LIPA gene, which carries the instructions for lysosomal acid lipase. This enzyme works inside lysosomes, the cell's recycling compartments, where it breaks down cholesterol esters and triglycerides so the body can use or clear them. In the infant form, the enzyme has essentially no activity, so these fats accumulate and trigger inflammation and organ damage. The condition is inherited in an autosomal recessive pattern. A child is affected only when both copies of the gene are altered, one from each parent. The parents are usually healthy carriers, and each pregnancy they have together carries a 1 in 4 chance of an affected child. Nothing a parent did during pregnancy causes it. LAL deficiency in all its forms is estimated to affect roughly 1 in 40,000 to 300,000 people, and the infant form is the rarer of the two.
Because the early signs (vomiting, diarrhea, poor growth) overlap with far more common problems such as milk protein intolerance, Wolman disease can be missed at first. Clues that point toward it include an enlarged liver and spleen, abnormal liver blood tests and calcium deposits in the adrenal glands (small hormone-producing glands on top of the kidneys), which can show up on imaging. The diagnosis is confirmed with a blood test that measures lysosomal acid lipase activity, which can be done on a few drops of blood dried on a card, together with genetic testing of the LIPA gene. When a family already has an affected child, a newborn brother or sister should be tested as soon as possible after birth so treatment can begin before damage builds up. Some countries are piloting newborn screening for the condition.
Treatment has changed the outlook for this disease. Sebelipase alfa (Kanuma) is a lab-made version of the missing enzyme, approved in the United States in 2015. It is given as an intravenous infusion, weekly for infants, and the dose is raised if growth, liver tests or organ size do not improve enough. In the main infant study, 6 of 9 treated babies lived past their first birthday, compared with none of 21 untreated infants in an earlier group; across two studies, about two-thirds of treated infants were estimated to be alive at age 5. Treated children grew better, their liver and spleen shrank, and anemia improved. Infusions continue long term, and treatment controls the disease rather than curing it. The enzyme can cause allergic reactions, occasionally severe ones (anaphylaxis), so it is started in a healthcare setting equipped to manage them, and most reactions happen during the infusion or within about 4 hours afterward. Because it is produced in the egg whites of specially bred chickens, a known serious egg allergy needs to be weighed with the care team. Diet is the second half of treatment. Breast milk and ordinary infant formulas are too high in fat, so infants are switched to specialized formulas that contain as little fat as possible, often with intravenous nutrition at first while the gut recovers. Vitamins A, D, E and K, essential fatty acids and iron are supplemented and checked, since deficiencies are common. A minimal-fat diet is generally expected to continue for life. A bone marrow (stem cell) transplant was the main option before enzyme therapy but carried very high risk; it is still considered for some children, typically after they have been stabilized on enzyme and diet.
The first months after diagnosis are usually intensive. Many infants spend time in hospital while infusions start and feeding is rebuilt, often through a feeding tube, and it can take weeks to months before a baby is fully fed by tube or mouth. Vomiting and diarrhea may persist for a while even as things improve. Growth is tracked closely, with arm circumference often more informative than weight because an enlarged liver and spleen add weight. With treatment, many children now survive well beyond infancy, gain weight, and develop normally, although long-term data only reach into early childhood and outcomes vary. Life involves regular infusions, a care team that usually includes metabolic specialists, liver specialists and a metabolic dietitian, and visits that become less frequent over time, often every few months once stable. Keeping fat intake very low gets harder as children grow, eat with peers and gain independence, so ongoing education and family support matter. Speech or feeding therapy may help children who are reluctant to eat by mouth after long tube feeding, and regular dental care matters on a higher-carbohydrate diet.
Ask for an evaluation if a baby in the first months of life has persistent vomiting or diarrhea with poor weight gain and a swollen belly, especially if a sibling or relative had LAL deficiency. If you are expecting a baby and a previous child was affected, plan testing with the care team before birth. For a child already in treatment, contact the care team promptly about signs of dehydration, continued weight loss, new jaundice, fever or a sudden change in alertness or feeding, since infants with this condition can decline quickly. Trouble breathing, swelling of the face or throat, or widespread hives during or in the hours after an infusion can be anaphylaxis: call 911.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Wolman Disease is like, what's helped you, or ask the community a question.